RDY Dr. Reddy's Laboratories Ltd. ADR Loading...

Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
11:50
Jul 30
Bloomberg Newswire (@business)
Dr. Reddy's Laboratories expects its generic anti-obesity drug to drive growth in the six.
Dr. Reddy's Laboratories expects its generic anti-obesity drug to drive growth in the six months through March.
RDY
07:04
Jul 30
Erez Israeli CEO, Dr. Reddy's Laboratories Bloomberg Markets
Dr. Reddy's sees strong Q3/Q4 recovery
After resolving semaglutide production scale-up issue by November, the company expects very healthy Q3 and Q4 earnings, supported by a weak rupee (costs in rupees, sales in dollars) and a strong product pipeline.
RDY
MED
01:34
Apr 30
BarbarianCap Twitter Analyst
Canada approved Dr. Reddy's generic Ozempic, a regulatory development with competitive.
Canada approved Dr. Reddy's generic Ozempic, a regulatory development with competitive implications.
RDY
LOW

About RDY Analyst Coverage

Buzzberg tracks RDY (Dr. Reddy's Laboratories Ltd. ADR) across 3 sources. 1 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (33%). 3 total trade ideas tracked. Latest voices: Bloomberg, Erez Israeli, BarbarianCap.